• Users Online: 138
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2021  |  Volume : 10  |  Issue : 1  |  Page : 55-58

Serum lactate dehydrogenase level in childhood acute lymphoblastic leukemia


1 Department of Hemato-Oncology, Child's Central Teaching Hospital, Baghdad, Iraq
2 Department of Nepherology, Al-Karama Teaching Hospital, Baghdad, Iraq

Correspondence Address:
Dr. Entisar Hadi Al-Shammary
Department of Hemato-Oncology, Child's Central Teaching Hospital, Baghdad
Iraq
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijh.ijh_4_21

Rights and Permissions

BACKGROUND: Acute lymphoblastic leukemia (ALL) is the most common malignancy in children. It accounts for one-fourth of all childhood cancers and 72% of all cases of childhood leukemia. OBJECTIVE: The objective was to evaluate the significant increase in serum lactate dehydrogenase (LDH) enzyme levels in patients with ALL with respect to patients' characters, clinical presentation, and patients' induction outcome. PATIENTS AND METHODS: A prospective study had been conducted during the period from November 1, 2017 to October 31, 2018, included 86 patients newly diagnosed ALL patients under the age of 15th years, admitted to the pediatric hemato-oncology unit in the Child's Central Teaching Hospital the data were collect from the patients, included, age, sex, clinical presentation, investigation and induction outcome of ALL patients to undergo analysis of study. RESULTS: Of a total (86) ALL patients started induction therapy, only (75/86) of them completed induction phase of therapy and those were enrolled in analysis of this study, while (11/86) did not complete induction therapy and excluded from the study (because 10 died, and one patient loss follow-up during induction). The mean age was 4.7 years. The male-to-female ratio was 1.26:1. LDH level ranged from 100 to 1995 U/L. There was a significant association between LDH level at day 0 and each of age and ALL risk group and no association with gender, hepatomegaly, splenomegaly, lymphadenopathy, central nervous system status, and induction outcome (remission/no remission). The mean of LDH levels at diagnosis was highly elevated in patients with ALL (726 ± 422 U/L); the response to induction treatment was observed by the significant decrease in mean LDH level (324 ± 201 U/L) at day 28th of treatment P value (0.0001). CONCLUSIONS: The serum LDH level was highly elevated at diagnosis in the majority of ALL patients and decreased significantly in response to chemotherapy. The estimation of serum LDH level is easy, and available, so it may be a helpful tool in evaluating the clinical aspect of the disease, the response to induction chemotherapy.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed252    
    Printed0    
    Emailed0    
    PDF Downloaded19    
    Comments [Add]    

Recommend this journal